Series Image

New cancer drug passes phase 1 trial?

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
%
chance
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
NovDecDecJanJan0%25%50%75%100%
6H
1D
1W
1M
ALL

What is Kalshi?
Kalshi is the first regulated platform in the US where you can trade on events, just like stocks. Think of it as the NYSE, but for things you relate to, care about, and understand.
Before 2026
$23,161vol

Order book
Order book


Rules summary
If a Phase II clinical trial has been announced for AOH1996 by December 31, 2025 (even if the trial has not started by that date), then the market resolves to Yes. Outcome verified from Clinicaltrials.gov.

Timeline and payout

About
AOH1996 is a novel cancer treatment drug that targets PCNA (proliferating cell nuclear antigen), a protein present in all dividing cells. Because AOH1996 inhibits PCNA, this type of drug is referred to as a PCNA inhibitor. Early tests suggest that AOH1996 may specifically target cancer cells while sparing normal cells. The drug is currently in Phase 1 clinical trials.
Show more
Series Image
New cancer drug passes phase 1 trial?
Buy Yes
Buy
Sell
Dollars
Pick a side
Contracts0
Average price
16¢
Payout if Yes wins
$0